WW International, Inc. (WW) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 29, 2024. WW International, Inc. operates in the weight management and health and wellness industry, reporting as a single segment. The company's business lines include Digital subscriptions, Workshops + Digital subscriptions, and Clinical subscriptions (via its acquisition of Sequence/WeightWatchers Clinic).
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|
| Net Revenues | $202.1 million | $408.6 million |
| Gross Profit | $137.3 million | $275.1 million |
| Gross Margin | 67.9% | 67.3% |
| Operating Income (Loss) | $35.9 million | ($233.4 million) |
| Net Income (Loss) | $23.3 million | ($324.6 million) |
| Diluted EPS | $0.29 | ($4.09) |
| Cash and Equivalents | $42.7 million (as of June 29, 2024) | |
| Total Debt (Principal) | $1,445.0 million | |
| Adjusted EBITDAS (YTD) | $59.1 million |
Material Changes vs. Prior Period
- Revenue Decline: Q2 2024 revenues decreased 10.9% year-over-year (YoY) to $202.1 million. YTD revenues decreased 12.8% to $408.6 million. The decline was driven by the discontinuation of the consumer products business (impacting "Other Revenues") and a shift in subscription mix toward lower-priced commitment periods and the Digital business.
- Q2 Profitability vs. YTD Loss: While Q2 2024 reported a net income of $23.3 million, the YTD period reported a net loss of $324.6 million. This discrepancy is primarily due to a $258.0 million non-cash impairment charge recorded in Q1 2024 related to indefinite-lived franchise rights acquired in the U.S., Australia, New Zealand, and the U.K.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased 27.5% in Q2 and 15.1% YTD, driven by reduced employee compensation and restructuring efforts. Marketing expenses increased 5.0% in Q2 due to higher online advertising spend.
- Interest Expense: Interest expense increased 18.7% in Q2 and 13.6% YTD, driven by higher base rates on the Term Loan Facility and the termination of interest rate swaps in March 2024.
Guidance, Outlook, and Risks
- Restructuring: On July 27, 2024 (subsequent to the period end), the company announced a new "2024 Restructuring Plan" to streamline operations. The company anticipates recording charges between $12.0 million and $15.0 million primarily for employee termination benefits in the second half of fiscal 2024.
- Liquidity and Debt Covenants: The company is currently not in compliance with its Consolidated First Lien Leverage Ratio covenant (actual 8.74:1.00 vs. required 5.25:1.00). Consequently, borrowing capacity under its Revolving Credit Facility is limited to 35% of commitments ($61.3 million) until compliance is restored.
- Asset Impairment Risk: Management noted that the fair value of franchise rights and goodwill is sensitive to assumptions regarding revenue growth and discount rates. Further impairments could occur if market conditions or business performance deteriorate.
- Outlook: Management expects to meet obligations through cash generated by operations, cash on hand, and limited revolver availability. They maintain flexibility to delay investments or reduce marketing spend if necessary.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's plan and timeline to reduce its leverage ratio to regain full access to its $175 million Revolving Credit Facility.
- Impairment Sustainability: Assess the assumptions used in the Q1 franchise rights impairment test and the risk of future impairments given the competitive clinical weight management market.
- Subscriber Trends: Monitor "Incoming Subscribers" and "Paid Weeks" metrics, particularly the continued decline in Workshops + Digital subscribers and the growth trajectory of the Clinical segment.
- Restructuring Execution: Track the actual costs and timing of the new 2024 Restructuring Plan announced in late July 2024.
- Cash Flow: Review the ability to generate positive operating cash flow given the significant cash burn in the first half of the year ($38.0 million used in operating activities).